Vielleicht hilft dir die (für mich u.a. hilfreiche) aktuellere Studie zu dem Thema noch weiter. Der zitierte Abschnitt bezieht sich auf ein Seminom.
http://annonc.oxfordjournals.org/content/26/5/833.full
Zitat:
|
About 80%–85% of patients with seminoma are diagnosed with CSI and ∼16% relapse during AS [5]. Enthusiasm for adjuvant radiotherapy has been tempered by the risk of radiation-induced secondary cancers and most European guidelines have removed this treatment option [1, 6]. Tumor size >4 cm and invasion of the rete testis were associated with an increased risk of relapse in an international retrospective study of 638 men, reporting relapse rates of 31.5%, 15.9% and 12% in those with both, one and neither risk factor, respectively [7]. Some subsequent reports questioned these findings [5, 8], but more recently, SWENOTECA reported that the presence of either risk factor independently increases the risk of relapse during AS significantly [9]. SWENOTECA reported a relapse rate of 2.9% in patients without risk factors compared with 21.7% in patients with 1–2 risk factors, although the number of men with two risk factors who were managed with surveillance was too small to assess whether their risk of relapse was higher than those with only one [9]. There are thus abundant data confirming our ability to identify low- and intermediate-risk patients, but fewer than one-third of the ‘high-risk’ patients are expected to relapse if managed with surveillance. For patients weighing AS versus ACT, knowing our best estimate of their risk of relapse is critical for them to be able to make an informed decision.
|
Das würde nach der SWENOTECA-Stellungnahme bedeuten:
Zitat:
|
The relapse-rate (RR) following AC was 6.2 %; in patients without risk factors 2.7 % compared to 9.4 % in patients with 1-2 risk factors. In patients followed by SURV the RR was 10 %; in patients without risk factors 2.9 %, compared to 21.7 % in patients with 1-2 risk factors.
|
http://meetinglibrary.asco.org/content/126404-144
VG, DD